Draft for consideration

Size: px
Start display at page:

Download "Draft for consideration"

Transcription

1 WHO OWNS SCIENCE? A DRAFT STATEMENT OF THE PROBLEM Draft for consideration Prepared by Professor John Sulston, Chair of isei Professor John Harris, Director of isei and Lord Alliance Professor of Bioethics Sarah Chan, Research Fellow, isei

2 WHO OWNS SCIENCE? THE MANCHESTER MANIFESTO Science and the innovation it generates is a vast enterprise: commercial and probono, public and private, industrial and educational, amateur and professional. It permeates our lives and shapes the world. Some would say it is the defining characteristic of humanity, stimulating and harnessing our innate curiosity and, more than any other endeavour, shaping our world and, increasingly, ourselves. For many reasons, some of which are set out below, it is increasingly important to consider the question who owns science?. The answer to this question will have broad-ranging implications: for scientific progress, for equity of access to scientific knowledge and its fruits and for the fair distribution of the benefits and the burdens of science and innovation in short, for global justice and human progress. This meeting will launch a process of attempting to achieve an expert consensus on the issues, the problems and dangers, the opportunities and hopefully also some of the solutions which will enable science and innovation to flourish in ways compatible with human progress (perhaps even survival) and global justice. Today we want to achieve two things: To identify the issues, problems and dangers surrounding questions of the ownership of science and innovation and to canvass some of the possible roads to finding answers and solutions. We also want your ideas on other key stakeholders and expertise we need to include so that at a subsequent meeting or meetings we can hope to arrive at an expert consensus on both problems and on at least some possible solutions. The idea is that this consensus document, tentatively called The Manchester Manifesto will be a point of departure both for future discussion and for progress towards solutions. Our approach The Manchester Consensus aims to bring together international experts from relevant disciplines to address the question of Who Owns Science? Led by two world-class research institutes at the University of Manchester, the Institute for Science, Ethics and Innovation and the Brooks World Poverty Institute, each of which is chaired by a Nobel Laureate (Professor John Sulston and Professor Joseph Stiglitz, respectively), the Consensus Group will represent a critical mass of research expertise that will be uniquely equipped to meet the challenges and problems outlined above. The Group s members are drawn from a broad range of academic disciplines and relevant sectors, including economics, science, innovation, law, philosophy, ethics and public policy. Our goal is not only to investigate the question of who owns science but to present and apply our findings to maximum effect in order to make a difference in the real world as to how science is used, and hence to build a better future for humanity. Statement of the problem Science is a rapidly growing industry. Beyond basic research, the commercialisation of technologies and development of new products from bench top to marketplace is a complex process. The way in which this process is managed, and in particular the way in which access to technologies is facilitated and controlled, is having and will inevitably have an increasing impact on the course of science and innovation. An important component of the innovation process is the idea of ownership of science and technology, particularly in the context of profiting from research and development. To manage the ownership of science and the fruits of research, an intricate system of

3 intellectual property law has developed. The justifications for IP law as it exists at present include the idea that it is necessary to facilitate scientific and economic benefit from innovation, and that it provides a fair and morally justifiable way of regulating access to these benefits. It is contended, however, that the current method of managing innovation (and perhaps in particular IP in its present form) suffers several disadvantages in terms of its effects on science and economic efficiency, and raises ethical issues because of its (often adverse) effects on people and populations. Whether this is in fact the case and, if so, what can be done about it (for if it is, then something should be done) is a broad question, but one of vital, perhaps paramount, importance, that will require investigation across a number of disciplines including law, economics, ethics and philosophy. Questions to be considered These are a few of the questions that a preliminary consideration of the subject suggests might be relevant in addressing the problem. This list should in no way be taken as comprehensive: we hope that through the discussion process, many other issues will come to light. We look forward to receiving your input on these in order to develop, as a group, our awareness of the full scope of the problem of Who Owns Science? Why is this an important question? - obvious significance from financial point of view profits to be gained from commercialisation of science and technology - because of its effect on people potential for science to do good or harm impact that ownership of science and how this is regulated will have to manage and modulate this potential - because the progress and the future of humanity depend in many ways on freely exploring science, and the ownership of science has vast potential to facilitate or impede this process of exploration What is science for what should science be for? - is it important to establish whether science ought to be for the public good or for something else? - what is the proper business of science? - What differing incentives are there for pursuing science - How do these differing incentives relate to the purposes for which science is or may be used? (eg pure curiosity; profit; harm or good?) - what are the reasons why science should be a public good?

4 because science can do good, and we always have powerful moral reasons to do good and avoid harming others.. because it is an institution that relies (and has relied on) public support, both financial, political and personal because it facilitates science itself, because publication, unfettered discourse and free communication amongst the global scientific community are crucial for the progress of science because the growing power of some of the products of science are capable of causing harm, either deliberate (e.g. biowarfare) or accidental, and the best defence is to ensure that practices are open to public scrutiny Some of the answers to questions concerning the proper business of science clearly indicate that science and innovation are broadly speaking in the public interest. If that is right, then the questions concerning the obligations of all to promote (or at least not damage) the public interest arise. To be clear about the obligations of all involved in science and about the proper scope of the aims of science we need to ask: What obligations does science have? - to the public (and to the various publics, local and global communities etc) the reciprocal side of the social contract and the public duty to support science - to funders and people who resource it to generate knowledge which may be used in various ways to generate profit to benefit humankind to advance human culture does the duty to create maximum profits and return on investment for shareholders of technology-based corporations conflict with the kinds of duties that (we may want to assert) exist towards others? If there is a conflict, how can/should it be resolved? - to those who contribute to the research, such as donors of biomaterials, other research participants, communities who contribute resources (eg biopiracy) - to science itself? (e.g. not to discredit science, not to do harm, to promote scientific progress, scientific integrity, honesty, openness and transparency, etc) How should these obligations be fulfilled? How (if at all) should their achievement be regulated or overseen? - can scientists regulate science? Is this effective? Desirable?

5 compare with other professional regulation bodies (eg GMC) what attempts have there been to establish internal regulation of science? National Academies of Science guidelines Peer-review and academic standards - what difficulties might be associated with national-level regulation of global science? eg transnational issues, data sharing, scientific tourism - and what about difficulties with international regulation that may not be responsive to the needs of local populations? eg internationally enforceable IP rights that may be inappropriate in terms of granting equitable access What are the effects of the current model of innovation and commercialisation of science? This question must be asked not just in the context of IP but the entire process of innovation, from support for commercialisation to marketing, distribution, regulation etc - in terms of access to technology in the general population? eg licensed vs generic drugs. Marketing as a way of controlling access and enforcing effective monopoly. - on communities in developing nations and on disadvantaged and vulnerable groups locally and globally? exclusive licensing preventing disadvantaged countries from accessing technology even where a parent company is itself unable to profit in this context? rise of generics companies in the developing world, especially India and China what effects does this have if exclusive rights patents are enforced internationally, TRIPS etc? What other effects might it have, eg health and safety? - on the process of research and development itself? Eg does the patent system and other devices for the ownership of IP discourage data sharing and timely publication because of the requirement that discoveries not be in the public domain at time of filing? does patenting allow suppression of ideas in terms of patent-sitting? This may be bad both because it hampers scientific progress and economically, because it is anti-competitive. does the entire system facilitate or frustrate science? For example, in the pharmaceutical industry, more money is currently spent on

6 marketing than on R&D, and new forms of old patents are rewarded more than true innovation What are the goals of managing science and innovation? What is IP law supposed to do? - reward creative effort just deserts, rights to benefit from invested labour. what is an appropriate reward? Cf what might be the differing incentives for science. Appropriate rewards are not necessarily always financial - hence encourage innovation and stimulate R&D is a system that ensures financial reward necessary for this purpose? And what level of recompense is required is the current form sufficient, is it over the top? - ensure public access to science (eg patents require publication after granting) Does the present model of intellectual property (in particular the patent system) fulfil these supposed aims? - this might be answered in light of some of the evidence gathered in response to questions above What should be done, and what can be done, to address the problems identified above? - is it possible to address these problems within the current system? compulsory licensing how is this to be managed? differential tariffs - what are the alternative methods of managing innovation, and what advantages and disadvantages might they offer? benefit sharing narrowly construed or more broadly in the sense of beneficence generally? are there reasons that benefit sharing should be restricted (or prioritised) to those who have contributed more to the research? Or is the need itself purely what gives rise to the obligation, irrespective of any prior contribution? remuneration based patents separation of research funding from production; prize competitions various sorts of access, including: unrestricted, open source software, fees according to GNP

7 corporate responsibility is corporate responsibility really a useful mechanism and if so, how can it be achieved? can individual obligations be extended to govern corporations? Is there any way of regulating this? what role might there be for influencing corporate actions through shareholder approval? This initial document formed the basis of discussion at a 1-day meeting of 40 national and international colleagues to mark the launch of the Institute for Science, Ethics and Innovation (isei) at The University of Manchester, on 5 July A further developed, finalised statement The Manchester Manifesto Towards a consensus on problems and solutions in IP and Innovation has been generated after a second meeting in January 2009 and will be available from our website shortly. For more information, contact: Institute for Science, Ethics and Innovation The University of Manchester Williamson Building Oxford Road Manchester M13 9PL UK tel : +44 (0) isei@manchester.ac.uk website :

The Challenge for SMEs. Government Policy

The Challenge for SMEs. Government Policy HOW CAN SMEs MAKE THE MOST OF OPPORTUNITIES AND CHALLENGES FOR THE UK INDUSTRIAL STRATEGY A speech delivered at the launch of a British Academy and Leverhulme funded project on knowledge co-creation between

More information

Public Research and Intellectual Property Rights

Public Research and Intellectual Property Rights Workshop on the Management of Intellectual Property Rights from Public Research OECD, Paris, 11 th December 2000 Public Research and Intellectual Property Rights Hugh Cameron PREST, University of Manchester

More information

ONLINE INTELLECTUAL PROPERTY COURSES BY FEDERATION OF INDIAN CHAMBERS OF COMMERCE AND INDUSTRY (FICCI) About FICCI Established in 1927, FICCI is the largest and oldest apex business organisation in India.

More information

Designing an ethical complement to the patent regime for pharmaceutical innovation. Pharma-Innovation Patent-2

Designing an ethical complement to the patent regime for pharmaceutical innovation. Pharma-Innovation Patent-2 Designing an ethical complement to the patent regime for pharmaceutical innovation Innova-P2 Project Background Innova-P2 is a 3-year Collaborative Project funded by the European Community s Seventh Framework

More information

An Essential Health and Biomedical R&D Treaty

An Essential Health and Biomedical R&D Treaty An Essential Health and Biomedical R&D Treaty Submission by Health Action International Global, Initiative for Health & Equity in Society, Knowledge Ecology International, Médecins Sans Frontières, Third

More information

Intellectual Property Rights in the Academic and Research Environment

Intellectual Property Rights in the Academic and Research Environment Intellectual Property Rights in the Academic and Research Environment Roger Elliott * Introduction The concept of intellectual property rights, which in the academic and research context are mainly concerned

More information

University IP and Technology Management. University IP and Technology Management

University IP and Technology Management. University IP and Technology Management University IP and Technology Management Yumiko Hamano WIPO University Initiative Program Innovation Division WIPO WIPO Overview IP and Innovation University IP and Technology Management Institutional IP

More information

Submission to the Productivity Commission inquiry into Intellectual Property Arrangements

Submission to the Productivity Commission inquiry into Intellectual Property Arrangements Submission to the Productivity Commission inquiry into Intellectual Property Arrangements DECEMBER 2015 Business Council of Australia December 2015 1 Contents About this submission 2 Key recommendations

More information

Guidelines on Standardization and Patent Pool Arrangements

Guidelines on Standardization and Patent Pool Arrangements Guidelines on Standardization and Patent Pool Arrangements Part 1 Introduction In industries experiencing innovation and technical change, such as the information technology sector, it is important to

More information

Efese, ethics in research

Efese, ethics in research faculty of law staatsrecht, bestuursrecht & bestuurskunde 02-06-2017 1 Efese, ethics in research Spetses, June 2017 Dr. Aline Klingenberg faculty of law staatsrecht, bestuursrecht & bestuurskunde 02-06-2017

More information

Theme 2016: "Linkages between Competition and Intellectual Property" India Habitat Centre New Delhi, India

Theme 2016: Linkages between Competition and Intellectual Property India Habitat Centre New Delhi, India World Competition Day 2016 5 th December Theme 2016: "Linkages between Competition and Intellectual Property" India Habitat Centre New Delhi, India Overview Keeping up with the tradition, CUTS Institute

More information

Enforcement of Intellectual Property Rights Frequently Asked Questions

Enforcement of Intellectual Property Rights Frequently Asked Questions EUROPEAN COMMISSION MEMO Brussels/Strasbourg, 1 July 2014 Enforcement of Intellectual Property Rights Frequently Asked Questions See also IP/14/760 I. EU Action Plan on enforcement of Intellectual Property

More information

Overview. How is technology transferred? What is technology transfer? What is Missouri S&T technology transfer?

Overview. How is technology transferred? What is technology transfer? What is Missouri S&T technology transfer? What is technology transfer? Technology transfer is a key component in the economic development mission of Missouri University of Science and Technology. Technology transfer complements the research mission

More information

The Role of the Intellectual Property Office

The Role of the Intellectual Property Office The Role of the Intellectual Property Office Intellectual Property Office is an operating name of the Patent Office The Hargreaves Review In 2011, Professor Ian Hargreaves published his review of intellectual

More information

IP and Technology Management for Universities

IP and Technology Management for Universities IP and Technology Management for Universities Yumiko Hamano Senior Program Officer WIPO University Initiative Innovation and Technology Transfer Section, Patent Division, WIPO Outline! University and IP!

More information

Flexibilities in the Patent System

Flexibilities in the Patent System Flexibilities in the Patent System Dr. N.S. Gopalakrishnan Professor, HRD Chair on IPR School of Legal Studies, Cochin University of Science & Technology, Cochin, Kerala 1 Introduction The Context Flexibilities

More information

A POLICY in REGARDS to INTELLECTUAL PROPERTY. OCTOBER UNIVERSITY for MODERN SCIENCES and ARTS (MSA)

A POLICY in REGARDS to INTELLECTUAL PROPERTY. OCTOBER UNIVERSITY for MODERN SCIENCES and ARTS (MSA) A POLICY in REGARDS to INTELLECTUAL PROPERTY OCTOBER UNIVERSITY for MODERN SCIENCES and ARTS (MSA) OBJECTIVE: The objective of October University for Modern Sciences and Arts (MSA) Intellectual Property

More information

UNCITRAL Third International Colloquium on Secured Transactions Session on Contractual Guide on IP Licensing (Vienna, March 3, 2010)

UNCITRAL Third International Colloquium on Secured Transactions Session on Contractual Guide on IP Licensing (Vienna, March 3, 2010) UNCITRAL Third International Colloquium on Secured Transactions Session on Contractual Guide on IP Licensing (Vienna, March 3, 2010) Basic contractual requirements on PATENT LICENSING Laurent Manderieux

More information

B) Issues to be Prioritised within the Proposed Global Strategy and Plan of Action:

B) Issues to be Prioritised within the Proposed Global Strategy and Plan of Action: INTERGOVERNMENTAL WORKING GROUP ON PUBLIC HEALTH, INNOVATION AND INTELLECTUAL PROPERTY EGA Submission to Section 1 Draft Global Strategy and Plan of Action The European Generic Medicines Association is

More information

Flexibilities in the Patent System

Flexibilities in the Patent System Flexibilities in the Patent System Joseph Straus, Munich WIPO Colloquium on Selected Patents Issues Geneva, February 16, 2007 J. Straus 2007 1 Topics to Consider Facts First Pre-TRIPS-Regime TRIPS & Mandatory

More information

Keywords: Synairgen plc, Southampton, collaboration, spin-out, asthma, COPD

Keywords: Synairgen plc, Southampton, collaboration, spin-out, asthma, COPD Professor Stephen Holgate is a member of the Infection, Inflammation and Repair Division in the University of Southampton School of Medicine. He is a co-founder and non-executive director of Synairgen

More information

Emerging biotechnologies. Nuffield Council on Bioethics Response from The Royal Academy of Engineering

Emerging biotechnologies. Nuffield Council on Bioethics Response from The Royal Academy of Engineering Emerging biotechnologies Nuffield Council on Bioethics Response from The Royal Academy of Engineering June 2011 1. How would you define an emerging technology and an emerging biotechnology? How have these

More information

ONR Strategy 2015 to 2020

ONR Strategy 2015 to 2020 Title of publication ONR Strategy 2015 to 2020 Office for Nuclear Regulation Page 1 of 5 Introduction Nick Baldwin, Chair The Energy Act 2013 provided for the creation of ONR as an independent, statutory

More information

Vice Chancellor s introduction

Vice Chancellor s introduction H O R I Z O N 2 0 2 0 2 Vice Chancellor s introduction Since its formation in 1991, the University of South Australia has pursued high aspirations with enthusiasm and success. This journey is ongoing and

More information

Written response to the public consultation on the European Commission Green Paper: From

Written response to the public consultation on the European Commission Green Paper: From EABIS THE ACADEMY OF BUSINESS IN SOCIETY POSITION PAPER: THE EUROPEAN UNION S COMMON STRATEGIC FRAMEWORK FOR FUTURE RESEARCH AND INNOVATION FUNDING Written response to the public consultation on the European

More information

The Defence of Basic

The Defence of Basic The Defence of Basic Research @DSweeneyHEFCE David Sweeney Executive Chair Designate, Research England Global Research-Intensive Universities Networks 27 th November 2017 The Defence of Basic Research?

More information

Our position. ICDPPC declaration on ethics and data protection in artificial intelligence

Our position. ICDPPC declaration on ethics and data protection in artificial intelligence ICDPPC declaration on ethics and data protection in artificial intelligence AmCham EU speaks for American companies committed to Europe on trade, investment and competitiveness issues. It aims to ensure

More information

European Charter for Access to Research Infrastructures - DRAFT

European Charter for Access to Research Infrastructures - DRAFT 13 May 2014 European Charter for Access to Research Infrastructures PREAMBLE - DRAFT Research Infrastructures are at the heart of the knowledge triangle of research, education and innovation and therefore

More information

Higher School of Economics, Vienna

Higher School of Economics, Vienna Open innovation and global networks - Symposium on Transatlantic EU-U.S. Cooperation on Innovation and Technology Transfer 22nd of March 2011 - Dr. Dirk Meissner Deputy Head and Research Professor Research

More information

Research integrity. House of Commons Science and Technology Committee. Submission from the Royal Academy of Engineering.

Research integrity. House of Commons Science and Technology Committee. Submission from the Royal Academy of Engineering. Research integrity House of Commons Science and Technology Committee Submission from the Royal Academy of Engineering March 2017 About the Royal Academy of Engineering As the UK's national academy for

More information

Discovery: From Concept to the Patient - The Business of Medical Discovery. Todd Sherer, Ph.D.

Discovery: From Concept to the Patient - The Business of Medical Discovery. Todd Sherer, Ph.D. Discovery: From Concept to the Patient - The Business of Medical Discovery Todd Sherer, Ph.D. Associate Vice President for Research and Director of OTT President Elect, Association of University Technology

More information

NCRIS Capability 5.7: Population Health and Clinical Data Linkage

NCRIS Capability 5.7: Population Health and Clinical Data Linkage NCRIS Capability 5.7: Population Health and Clinical Data Linkage National Collaborative Research Infrastructure Strategy Issues Paper July 2007 Issues Paper Version 1: Population Health and Clinical Data

More information

Organisation: Microsoft Corporation. Summary

Organisation: Microsoft Corporation. Summary Organisation: Microsoft Corporation Summary Microsoft welcomes Ofcom s leadership in the discussion of how best to manage licence-exempt use of spectrum in the future. We believe that licenceexemption

More information

Settlement of Pharma Disputes and Competition Law in Korea

Settlement of Pharma Disputes and Competition Law in Korea Settlement of Pharma Disputes and Competition Law in Korea October 22, 2012 Monica Hyon-Kyong Leeu AIPPI PHARMA WORKSHOP I Topics Patent Disputes in Korean Pharma Industry Korean Competition Law and KFTC

More information

A NEW INCENTIVE SYSTEM FOR TECHNOLOGICAL INNOVATION IN DEVELOPING COUNTRIES

A NEW INCENTIVE SYSTEM FOR TECHNOLOGICAL INNOVATION IN DEVELOPING COUNTRIES A NEW INCENTIVE SYSTEM FOR TECHNOLOGICAL INNOVATION IN DEVELOPING COUNTRIES Miguel A. Maito Eduardo Franciosi Introduction This work has been inspired by the analysis and discussion of Professor Joseph

More information

Patents & Innovation In the Pharmaceutical Industry: Literature Review. Jonathan Gock POL 459 Prof. Hira Fall 09

Patents & Innovation In the Pharmaceutical Industry: Literature Review. Jonathan Gock POL 459 Prof. Hira Fall 09 Patents & Innovation In the Pharmaceutical Industry: Literature Review Jonathan Gock POL 459 Prof. Hira Fall 09 1 Introduction In light of recent health epidemics (e.g. H1N1) and the reality of an ever-aging

More information

Technology transfer offices: a boost to licensing in Mexico

Technology transfer offices: a boost to licensing in Mexico Technology transfer offices: a boost to licensing in Mexico A drive towards establishing organised technology transfer offices in universities has obvious benefits for domestic companies, but may also

More information

Human Rights Approach

Human Rights Approach Human Rights Approach Bartha M. Knoppers Director of the Centre of Genomics and Policy, McGill Chair, GA4GH Regulatory and Ethics Working Group Canada Research Chair in Law and Medicine I have no Conflicts

More information

Canada s Intellectual Property (IP) Strategy submission from Polytechnics Canada

Canada s Intellectual Property (IP) Strategy submission from Polytechnics Canada Canada s Intellectual Property (IP) Strategy submission from Polytechnics Canada 170715 Polytechnics Canada is a national association of Canada s leading polytechnics, colleges and institutes of technology,

More information

Agenda Item 4: Transport Strategy: Vision and Objectives

Agenda Item 4: Transport Strategy: Vision and Objectives Strategic Transport Forum 16 th March 2018 englandseconomicheartland@b uckscc.gov.uk Agenda Item 4: Transport Strategy: Vision and Objectives Recommendation: It is recommended that the meeting consider

More information

RECOMMENDATIONS. COMMISSION RECOMMENDATION (EU) 2018/790 of 25 April 2018 on access to and preservation of scientific information

RECOMMENDATIONS. COMMISSION RECOMMENDATION (EU) 2018/790 of 25 April 2018 on access to and preservation of scientific information L 134/12 RECOMMDATIONS COMMISSION RECOMMDATION (EU) 2018/790 of 25 April 2018 on access to and preservation of scientific information THE EUROPEAN COMMISSION, Having regard to the Treaty on the Functioning

More information

Technology Leadership Course Descriptions

Technology Leadership Course Descriptions ENG BE 700 A1 Advanced Biomedical Design and Development (two semesters, eight credits) Significant advances in medical technology require a profound understanding of clinical needs, the engineering skills

More information

ICC POSITION ON LEGITIMATE INTERESTS

ICC POSITION ON LEGITIMATE INTERESTS ICC POSITION ON LEGITIMATE INTERESTS POLICY STATEMENT Prepared by the ICC Commission on the Digital Economy Summary and highlights This statement outlines the International Chamber of Commerce s (ICC)

More information

UNCTAD Ad Hoc Expert Meeting on the Green Economy: Trade and Sustainable Development Implications November

UNCTAD Ad Hoc Expert Meeting on the Green Economy: Trade and Sustainable Development Implications November UNCTAD Ad Hoc Expert Meeting on the Green Economy: Trade and Sustainable Development Implications 8-10 November Panel 3: ENHANCING TECHNOLOGY ACCESS AND TRANSFER Good morning Ladies and Gentlemen. On behalf

More information

Computer Ethics. Dr. Aiman El-Maleh. King Fahd University of Petroleum & Minerals Computer Engineering Department COE 390 Seminar Term 062

Computer Ethics. Dr. Aiman El-Maleh. King Fahd University of Petroleum & Minerals Computer Engineering Department COE 390 Seminar Term 062 Computer Ethics Dr. Aiman El-Maleh King Fahd University of Petroleum & Minerals Computer Engineering Department COE 390 Seminar Term 062 Outline What are ethics? Professional ethics Engineering ethics

More information

National Standard of the People s Republic of China

National Standard of the People s Republic of China ICS 01.120 A 00 National Standard of the People s Republic of China GB/T XXXXX.1 201X Association standardization Part 1: Guidelines for good practice Click here to add logos consistent with international

More information

Dear Secretary of State Parreira, Dear President Aires-Barros, Dear ALLEA delegates, esteemed faculty of today s workshop,

Dear Secretary of State Parreira, Dear President Aires-Barros, Dear ALLEA delegates, esteemed faculty of today s workshop, Welcome Address on the occasion of the Scientific Symposium Science and Research in Europe: past, present and future 15 Years of Lisbon Agenda in the context of the ALLEA General Assembly 2015 23 April

More information

NHS Greater Glasgow and Clyde Health Board. Policy on the Management of Intellectual Property

NHS Greater Glasgow and Clyde Health Board. Policy on the Management of Intellectual Property NHS Originated by: David Wyper and Lorna Kelly Title: Board Date: 6/05/2008 Authorised by: Date: 1 Introduction 1.1 NHS organisations are obliged to manage their Research & Development (R&D) to improve

More information

Getting the evidence: Using research in policy making

Getting the evidence: Using research in policy making Getting the evidence: Using research in policy making REPORT BY THE COMPTROLLER AND AUDITOR GENERAL HC 586-I Session 2002-2003: 16 April 2003 LONDON: The Stationery Office 14.00 Two volumes not to be sold

More information

THE LABORATORY ANIMAL BREEDERS ASSOCIATION OF GREAT BRITAIN

THE LABORATORY ANIMAL BREEDERS ASSOCIATION OF GREAT BRITAIN THE LABORATORY ANIMAL BREEDERS ASSOCIATION OF GREAT BRITAIN www.laba-uk.com Response from Laboratory Animal Breeders Association to House of Lords Inquiry into the Revision of the Directive on the Protection

More information

Intellectual Property Policy. DNDi POLICIES

Intellectual Property Policy. DNDi POLICIES Intellectual Property Policy DNDi POLICIES DNDi hereby adopts the following intellectual property (IP) policy: I. Preamble The mission of DNDi is to develop safe, effective and affordable new treatments

More information

ABHI Response to the Kennedy short study on Valuing Innovation

ABHI Response to the Kennedy short study on Valuing Innovation ABHI Response to the Kennedy short study on Valuing Innovation Introduction 1. The Association of British Healthcare Industries (ABHI) is the industry association for the UK medical technology sector.

More information

Loyola University Maryland Provisional Policies and Procedures for Intellectual Property, Copyrights, and Patents

Loyola University Maryland Provisional Policies and Procedures for Intellectual Property, Copyrights, and Patents Loyola University Maryland Provisional Policies and Procedures for Intellectual Property, Copyrights, and Patents Approved by Loyola Conference on May 2, 2006 Introduction In the course of fulfilling the

More information

National Innovation System of Mongolia

National Innovation System of Mongolia National Innovation System of Mongolia Academician Enkhtuvshin B. Mongolians are people with rich tradition of knowledge. When the Great Mongolian Empire was established in the heart of Asia, Chinggis

More information

The Standardization and the Patent Issue in Telemedicine

The Standardization and the Patent Issue in Telemedicine The Standardization and the Patent Issue in Telemedicine Makoto ISHIKAWA Associate Professor Kyoto University of Education Standardization in telemedicine Telemedicine is the medical care using information

More information

Innovation Office. Intellectual Property at the Nelson Mandela University: A Brief Introduction. Creating value for tomorrow

Innovation Office. Intellectual Property at the Nelson Mandela University: A Brief Introduction. Creating value for tomorrow Innovation Office Creating value for tomorrow PO Box 77000 Nelson Mandela University Port Elizabeth 6031 South Africa www.mandela.ac.za Innovation Office Main Building Floor 12 041 504 4309 innovation@mandela.ac.za

More information

Draft Plan of Action Chair's Text Status 3 May 2008

Draft Plan of Action Chair's Text Status 3 May 2008 Draft Plan of Action Chair's Text Status 3 May 2008 Explanation by the Chair of the Drafting Group on the Plan of Action of the 'Stakeholder' Column in the attached table Discussed Text - White background

More information

INTELLECTUAL PROPERY RIGHTS: ECONOMY Vs SCIENCE &TECHNOLOGY. Sankar Narayanan.S System Analyst, Anna University Coimbatore

INTELLECTUAL PROPERY RIGHTS: ECONOMY Vs SCIENCE &TECHNOLOGY. Sankar Narayanan.S System Analyst, Anna University Coimbatore Volume 1 Issue 1 May 2010 pp. 6-10 http://www.iaeme.com/ijipr.html I J I P R I A E M E INTELLECTUAL PROPERY RIGHTS: ECONOMY Vs SCIENCE &TECHNOLOGY ABSTRACT Sankar Narayanan.S System Analyst, Anna University

More information

Intellectual Property Management - How to capture, protect and exploit your ideas

Intellectual Property Management - How to capture, protect and exploit your ideas Intellectual Property Management - How to capture, protect and exploit your ideas 13 th February 2013 Gillian Davis & Julian Peck Cambridge Enterprise Limited, University of Cambridge Overview Disclosure

More information

Ethical and Legal Issues of Design ELEC 421

Ethical and Legal Issues of Design ELEC 421 Ethical and Legal Issues of Design ELEC 421 What is a Profession? Profession A calling requiring special knowledge and often long and intense academic preparation. (source: Webster s Collegiate Dictionary)

More information

Topic 3 - Chapter II.B Primary consideration before drafting a patent application. Emmanuel E. Jelsch European Patent Attorney

Topic 3 - Chapter II.B Primary consideration before drafting a patent application. Emmanuel E. Jelsch European Patent Attorney Topic 3 - Chapter II.B Primary consideration before drafting a patent application Emmanuel E. Jelsch European Patent Attorney Table of Contents Detailed Overview of Patents Patent Laws Patents Overview

More information

UNIVERSITIES AND TECHNOLOGY TRANSFER PATENT ATTORNEYS TRADE MARK ATTORNEYS

UNIVERSITIES AND TECHNOLOGY TRANSFER PATENT ATTORNEYS TRADE MARK ATTORNEYS UNIVERSITIES AND TECHNOLOGY TRANSFER PATENT ATTORNEYS TRADE MARK ATTORNEYS INDEPENDENT THINKING. COLLECTIVE EXCELLENCE. Your intellectual property assets are of great value to you. To help you to secure,

More information

THE AMERICAN INTELLECTUAL PROPERTY LAW ASSOCIATION RECOMMENDATIONS REGARDING QUALIFICATIONS FOR

THE AMERICAN INTELLECTUAL PROPERTY LAW ASSOCIATION RECOMMENDATIONS REGARDING QUALIFICATIONS FOR THE AMERICAN INTELLECTUAL PROPERTY LAW ASSOCIATION RECOMMENDATIONS REGARDING QUALIFICATIONS FOR THE NEXT DIRECTOR AND DEPUTY DIRECTOR OF THE U.S. PATENT AND TRADEMARK OFFICE Revised and approved, AIPLA

More information

WPI Intellectual Property A day in the life of the tech transfer office. Todd Keiller Director, Intellectual Property and Innovation

WPI Intellectual Property A day in the life of the tech transfer office. Todd Keiller Director, Intellectual Property and Innovation WPI Intellectual Property A day in the life of the tech transfer office Todd Keiller Director, Intellectual Property and Innovation Who does research? Federal and state governments Defense, public health,

More information

Towards a Magna Carta for Data

Towards a Magna Carta for Data Towards a Magna Carta for Data Expert Opinion Piece: Engineering and Computer Science Committee February 2017 Expert Opinion Piece: Engineering and Computer Science Committee Context Big Data is a frontier

More information

The 45 Adopted Recommendations under the WIPO Development Agenda

The 45 Adopted Recommendations under the WIPO Development Agenda The 45 Adopted Recommendations under the WIPO Development Agenda * Recommendations with an asterisk were identified by the 2007 General Assembly for immediate implementation Cluster A: Technical Assistance

More information

Comics as Contracts 2016/04/05 1

Comics as Contracts 2016/04/05 1 Comics as Contracts MINDFUL CONTRACTS 2016/04/05 1 Comic Contracts o o o Characters represent the parties Interaction and dialogue represent the terms Parties sign the comic as their Contract 2016/04/05

More information

ECU Research Commercialisation

ECU Research Commercialisation The Framework This framework describes the principles, elements and organisational characteristics that define the commercialisation function and its place and priority within ECU. Firstly, care has been

More information

Finland s drive to become a world leader in open science

Finland s drive to become a world leader in open science Finland s drive to become a world leader in open science EDITORIAL Kai Ekholm Solutionsbased future lies ahead Open science is rapidly developing all over the world. For some time now Open Access (OA)

More information

Parenteral Nutrition Down Under Inc. (PNDU) Working with Pharmaceutical Companies Policy (Policy)

Parenteral Nutrition Down Under Inc. (PNDU) Working with Pharmaceutical Companies Policy (Policy) Parenteral Nutrition Down Under Inc. (PNDU) Working with Pharmaceutical Companies Policy (Policy) BACKGROUND (Reason or Purpose) The purpose of this Policy is to provide clear principles and guidance about

More information

Functionality of the Nagoya ABS Protocol with a view to AnGR and a side-look to Anti- Conterfeiting Trade Agreement (ACTA)

Functionality of the Nagoya ABS Protocol with a view to AnGR and a side-look to Anti- Conterfeiting Trade Agreement (ACTA) Functionality of the Nagoya ABS Protocol with a view to AnGR and a side-look to Anti- Conterfeiting Trade Agreement (ACTA) Morten Walløe Tvedt Senior research fellow International Technical Expert Workshop

More information

Standing Committee on the Law of Patents

Standing Committee on the Law of Patents E SCP/24/4 ORIGINAL: ENGLISH DATE: JUNE 29, 2016 Standing Committee on the Law of Patents Twenty-Fourth Session Geneva, June 27 to 30, 2016 PROPOSAL BY THE AFRICAN GROUP FOR A WIPO WORK PROGRAM ON PATENTS

More information

(Fig.) JPMA Industry Vision 2025

(Fig.) JPMA Industry Vision 2025 2. JPMA Industry Vision 2025 Against the background of the changing environment surrounding the pharmaceutical industry and the future predictions *1, we prepared JPMA Industry Vision 2025 Bringing Innovation

More information

Green Paper - From Challenges to Opportunities: Towards a Common Strategic Framework. for EU Research and Innovation Funding

Green Paper - From Challenges to Opportunities: Towards a Common Strategic Framework. for EU Research and Innovation Funding Green Paper - From Challenges to Opportunities: Towards a Common Strategic Framework for EU Research and Innovation Funding Position of the European Brain Council (EBC) Introduction The European Brain

More information

Open Science for the 21 st century. A declaration of ALL European Academies

Open Science for the 21 st century. A declaration of ALL European Academies connecting excellence Open Science for the 21 st century A declaration of ALL European Academies presented at a special session with Mme Neelie Kroes, Vice-President of the European Commission, and Commissioner

More information

UW REGULATION Patents and Copyrights

UW REGULATION Patents and Copyrights UW REGULATION 3-641 Patents and Copyrights I. GENERAL INFORMATION The Vice President for Research and Economic Development is the University of Wyoming officer responsible for articulating policy and procedures

More information

Session 2: Essential IP Knowledge to Protect your Technology in China. Dr. Martin Seybold Kanzlei Dr. Seybold, Beijing

Session 2: Essential IP Knowledge to Protect your Technology in China. Dr. Martin Seybold Kanzlei Dr. Seybold, Beijing Session 2: Essential IP Knowledge to Protect your Technology in China Dr. Martin Seybold Kanzlei Dr. Seybold, Beijing Dr. Martin Seybold Kanzlei Dr. Seybold, Beijing Founder: Kanzlei Dr. Seybold - legal

More information

Statement by the BIAC Committee on Technology and Industry on THE IMPACT OF INTELLECTUAL PROPERTY PROTECTION ON INNOVATION AND TECHNOLOGY DEVELOPMENT

Statement by the BIAC Committee on Technology and Industry on THE IMPACT OF INTELLECTUAL PROPERTY PROTECTION ON INNOVATION AND TECHNOLOGY DEVELOPMENT Business and Industry Advisory Committee to the OECD OECD Comité Consultatif Economique et Industriel Auprès de l l OCDE Statement by the BIAC Committee on Technology and Industry on THE IMPACT OF INTELLECTUAL

More information

AN OVERVIEW OF THE STATE OF MARINE SPATIAL PLANNING IN THE MEDITERRANEAN COUNTRIES MALTA REPORT

AN OVERVIEW OF THE STATE OF MARINE SPATIAL PLANNING IN THE MEDITERRANEAN COUNTRIES MALTA REPORT AN OVERVIEW OF THE STATE OF MARINE SPATIAL PLANNING IN THE MEDITERRANEAN COUNTRIES MALTA REPORT Malta Environment & Planning Authority May 2007 AN OVERVIEW OF THE STATE OF MARINE SPATIAL PLANNING IN THE

More information

POLICY PHILOSOPHY DEFINITIONS AC.2.11 INTELLECTUAL PROPERTY. Programs and Curriculum. APPROVED: Chair, on Behalf of SAIT s Board of Governors

POLICY PHILOSOPHY DEFINITIONS AC.2.11 INTELLECTUAL PROPERTY. Programs and Curriculum. APPROVED: Chair, on Behalf of SAIT s Board of Governors Section: Subject: Academic/Student (AC) Programs and Curriculum AC.2.11 INTELLECTUAL PROPERTY Legislation: Copyright Act (R.S.C., 1985, c.c-42); Patent Act (R.S.C., 1985, c.p-4); Trade-marks Act (R.S.C.

More information

GSA SUMMARY REPORT OF EQUALITY CONSIDERATION AND ASSESSMENT OF EQUALITY IMPACT. PGT Ethics Policy. New: Existing/Reviewed: Revised/Updated:

GSA SUMMARY REPORT OF EQUALITY CONSIDERATION AND ASSESSMENT OF EQUALITY IMPACT. PGT Ethics Policy. New: Existing/Reviewed: Revised/Updated: GSA SUMMARY REPORT OF EQUALITY CONSIDERATION AND ASSESSMENT OF EQUALITY IMPACT Date of Assessment: 11/12/16 School/Department: Lead member of staff: Location of impact assessment documentation (contact

More information

Globalisation increasingly affects how companies in OECD countries

Globalisation increasingly affects how companies in OECD countries ISBN 978-92-64-04767-9 Open Innovation in Global Networks OECD 2008 Executive Summary Globalisation increasingly affects how companies in OECD countries operate, compete and innovate, both at home and

More information

THEFUTURERAILWAY THE INDUSTRY S RAIL TECHNICAL STRATEGY 2012 INNOVATION

THEFUTURERAILWAY THE INDUSTRY S RAIL TECHNICAL STRATEGY 2012 INNOVATION 73 INNOVATION 74 VISION A dynamic industry that innovates to evolve, grow and attract the best entrepreneurial talent OBJECTIVES Innovation makes a significant and continuing contribution to rail business

More information

TRANSFORMATIONAL GOALS FOR THE 21ST CENTURY

TRANSFORMATIONAL GOALS FOR THE 21ST CENTURY TRANSFORMATIONAL GOALS FOR THE 21ST CENTURY The president's 21st century fund for excellence THE UNIVERSITY OF RHODE ISLAND The University of Rhode Island is a community that thinks big and wants to share

More information

NHS Next Stage Review: Innovation

NHS Next Stage Review: Innovation NHS Next Stage Review: Innovation January 2008 Introduction 1. The Academy of Medical Sciences welcomes the opportunity to contribute to the NHS Next Stage Review. In this short response we have focused

More information

Presentation to NAS Committee on IP Management in Standards-Setting Processes. Dan Bart President and CEO Valley View Corporation November 4, 2011

Presentation to NAS Committee on IP Management in Standards-Setting Processes. Dan Bart President and CEO Valley View Corporation November 4, 2011 Presentation to NAS Committee on IP Management in Standards-Setting Processes Dan Bart President and CEO Valley View Corporation November 4, 2011 Who is Dan Bart? Current Chairman of the ANSI IPR Policy

More information

The Developing World and the Role of Information and. Communication Technologies

The Developing World and the Role of Information and. Communication Technologies The Developing World and the Role of Information and Communication Technologies Inventions and Patents 6.901 Presented by Mohamed Haji 12/14/05 The Developing World and the Role of Information Communication

More information

Public Hearings Concerning the Evolving Intellectual Property Marketplace

Public Hearings Concerning the Evolving Intellectual Property Marketplace [Billing Code: 6750-01-S] FEDERAL TRADE COMMISSION Public Hearings Concerning the Evolving Intellectual Property Marketplace AGENCY: Federal Trade Commission. ACTION: Notice of Public Hearings SUMMARY:

More information

Dr. Biswajit Dhar Professor, Jawaharlal Nehru University, India and Member DA9 Advisory Board

Dr. Biswajit Dhar Professor, Jawaharlal Nehru University, India and Member DA9 Advisory Board Dr. Biswajit Dhar Professor, Jawaharlal Nehru University, India and Member DA9 Advisory Board Intellectual Property Rights in Preferential Trade Agreements Many Preferential Trade Agreements (PTAs) adopted

More information

SHORT SUMMARY REPORT OF THE WORKSHOP ON GENETIC INVENTIONS, INTELLECTUAL PROPERTY RIGHTS AND LICENSING PRACTICES

SHORT SUMMARY REPORT OF THE WORKSHOP ON GENETIC INVENTIONS, INTELLECTUAL PROPERTY RIGHTS AND LICENSING PRACTICES SHORT SUMMARY REPORT OF THE WORKSHOP ON GENETIC INVENTIONS, INTELLECTUAL PROPERTY RIGHTS AND LICENSING PRACTICES Held in Berlin, Germany 24 and 25 January 2002 1 I. The Berlin Experts Workshop On January

More information

The business of Intellectual Property

The business of Intellectual Property The business of Intellectual Property Including IP patent value funds 15 th September 2008 Julian Nolan Julian Nolan - background Applications Engineer National Instruments, USA Business Development Director

More information

TRIPS, FTAs and BITs: Impact on Domestic IP- and Innovation Strategies in Developing Countries

TRIPS, FTAs and BITs: Impact on Domestic IP- and Innovation Strategies in Developing Countries Innovation, Creativity and IP Policy: An Indo-European Dialogue TRIPS, FTAs and BITs: Impact on Domestic IP- and Innovation Strategies in Developing Countries Henning Grosse Ruse NUJS & MPI Collaborative

More information

Spectrum Management Fundamentals

Spectrum Management Fundamentals Spectrum Management Fundamentals Part 2 Version 3 National Spectrum Management Spectrum Management Goals Establishing a Management Framework Spectrum Management processes are established in a framework

More information

What is Intellectual Property?

What is Intellectual Property? What is Intellectual Property? Watch: Courtesy Swatch AG What is Intellectual Property? Table of Contents Page What is Intellectual Property? 2 What is a Patent? 5 What is a Trademark? 8 What is an Industrial

More information

Intellectual Property Rights and Development CARLOS M. CORREA

Intellectual Property Rights and Development CARLOS M. CORREA Intellectual Property Rights and Development CARLOS M. CORREA Proposal by Argentina and Brazil (2004) IP protection is a policy instrument the operation of which may, in actual practice, produce benefits

More information

Role of Intellectual Property in Science, Technology and Development

Role of Intellectual Property in Science, Technology and Development Role of Intellectual Property in Science, Technology and Development Workshop on Technology for Development: Innovation Policies for SDGS in the Arab Region - Amman, 15-19 April 2018 Tamara Nanayakkara,

More information

TRIPS Post Grant Flexibilities: Key Exceptions to Patent Holders' Rights. David Vivas Eugui

TRIPS Post Grant Flexibilities: Key Exceptions to Patent Holders' Rights. David Vivas Eugui TRIPS Post Grant Flexibilities: Key Exceptions to Patent Holders' David Vivas Eugui dvivas@ictsd.ch OVERVIEW OF PRESENTATION Patent holders rights Article 30 TRIPS Agreement on patent exceptions The scientific

More information

Counterfeit, Falsified and Substandard Medicines

Counterfeit, Falsified and Substandard Medicines Meeting Summary Counterfeit, Falsified and Substandard Medicines Charles Clift Senior Research Consultant, Centre on Global Health Security December 2010 The views expressed in this document are the sole

More information

TRIPS and Access to Medicines. WR Briefing

TRIPS and Access to Medicines. WR Briefing TRIPS and Access to Medicines WR Briefing Outline What is TRIPS How does it affect access to medicines What are the TRIPS flexibilities? What are extra-trips provisions? How do the extra-trips provisions

More information

OECD Innovation Strategy: Key Findings

OECD Innovation Strategy: Key Findings The Voice of OECD Business March 2010 OECD Innovation Strategy: Key Findings (SG/INNOV(2010)1) BIAC COMMENTS General comments BIAC has strongly supported the development of the horizontal OECD Innovation

More information